Advance Online
Two older men smiling in a kitchen.
Advance Online

New Treatment for PsA

The U.S. FDA approves upadacitinib for the treatment of adults with active psoriatic arthritis.

Following two Phase 3 clinical studies which demonstrated efficacy and safety, the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) inhibitors. [1]

RINVOQ® is a selective JAK inhibitor that showed greater inhibitory potency for JAK-1 vs JAK-2, JAK-3, and TYK-2. It is available in a once daily 15 mg dose. [1]

“Many adults still struggle to find a treatment option that helps them lower their disease activity,” said Iain McInnes, professor of medicine and Versus Arthritis professor of rheumatology at University of Glasgow, U.K., and lead investigator of the SELECT-PsA 1 trial. “With this FDA approval, RINVOQ has the potential to help more people find meaningful relief from the signs and symptoms of psoriatic arthritis that they see and feel and to help reach their treatment goals.” [1]

This is the second FDA-approved indication for RINVOQ®. It was previously approved for rheumatoid arthritis in 2019. [1]

Psoriatic Arthritis

PsA affects one in three people with psoriasis and can develop at any age.

Learn more

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2021 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.